Who Is The Largest Pharmacy In The Us?

According to a recent analysis from the Drug Channels Institute, the total income generated from the dispensing of prescription medications at pharmacies in the United States reached a new high of $446 billion in 2019. A significant portion of this money was generated by CVS Health and Walgreens.

1. The following is a ranking of the 15 largest pharmacies in the United States in 2019, based on the total income generated from the dispensing of prescription drugs: 1.
2. CVS Health, with 109 billion dollars in revenue 2.
3. Walgreens — $84.3 billion 3.
4. Cigna/Express Scripts — $45.8 billion 4.
5. OptumRx, which is owned by UnitedHealth Group, is valued at $25.8 billion 5.

Walmart — $21.2 billion 6. The Kroger Company, with a revenue of $14.0 billion 7. Rite Aid, with a revenue of $11 billion 8. Humana Pharmacy Solutions, with a revenue of 6.9 billion dollars 9. Albertsons — $5.1 billion 10. Diplomat Pharmacy, with an annual revenue of $4.5 billion 11.

What are the top for pharmacies in the US?

The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers will be made available for download by the Drug Channels Institute the following week. Our well-known and thorough investigation into the drug pricing, reimbursement, and dispensing system has now reached its thirteenth iteration and is in its thirteenth edition.

This initial look at the 15 largest organizations, ranked by total U.S. prescription dispensing revenues for the calendar year 2021 can be found in the exhibit that can be seen below, which is one of 216 that can be found in our new study. Revenues from the sale of prescription drugs in the United States hit a new high of $501 billion in 2021.

When compared to their share in 2020, the overall share held by the 15 largest firms is somewhat smaller now. This is mostly attributable to growth rates that are lower than average in the retail and long-term care pharmacy sectors. A reorganization of this list may take place in 2022 as a result of the impending changes in business that I will outline below.

1. Continue reading as we present our most recent informational update on the rapidly developing pharmacy and PBM business.
2. By clicking this link, you will be able to get a free summary of the full report, which will provide you with a look at the most important trends in the industry, the table of contents, and a list of the exhibits.

If you place your purchase before the 28th of March in 2022, you will receive a special reduced price. Put them on the rack: THE TOP 15 The following table presents projections provided by DCI regarding the ranking of the major pharmacies for the year 2021 based on total revenues generated from the dispensing of prescription drugs, omitting income generated from the administration of COVID-19 vaccinations. In 2021, the top seven dispensing pharmacies in the United States were CVS Health, Walgreens Boots Alliance, Cigna, UnitedHealth Group, Walmart, and Kroger, and Rite Aid. These pharmacies accounted for more than 70 percent of the revenue generated from the sale of prescription drugs in the United States.

Nearly 77 percent of overall dispensing revenues came from retail, mail, long-term care, and specialty pharmacies, and those revenues were accounted for by the top 15 pharmacies. When compared with their share in 2020, the overall share held by the 15 largest firms was lower. This was mostly attributable to below-market growth rates seen by retail and long-term care pharmacies.

In the following parts of our new research, we address the market shifts and acquisitions that had an impact on the 2021 revenue and growth rates for the major companies: Section 2.3.3, Section 3.3.2, and Section 5.2.2. Analysis from previous years shows that five of the major pharmacies are controlled by pharmacy benefit managers (PBMs), including Caremark (CVS Health), Express Scripts (Cigna), Envolve Health (Centene), Humana, and OptumRx.

1. These pharmacies include central-fill mail and specialty pharmacies (UnitedHealth Group).
2. The most prominent PBMs, specialty pharmacies, and insurers have recently merged their operations to become vertically integrated corporations.
3. The income amounts displayed in the chart located above are a compilation of the dispensing revenues generated by all of the organizations’ constituent businesses.

The dispensing of more expensive speciality pharmaceuticals, which accounted for more than 38% of the pharmacy industry’s prescription sales in 2021, is driving revenue growth at the pharmacies owned and operated by pharmacy benefit managers (PBMs). PBMs’ capacity to generate revenue through specialized pharmacy dispensing and payments from manufacturers, as we demonstrate in Section 11.2.3.

1. of our latest study, has become critically important.
2. Even when rebates are factored in, the percentage of a plan sponsor’s pharmacy benefit expenses that are attributable to specialty medications continues to be more than that percentage.
3. As a result, PBMs and third-party payers have been more proactive in their management of speciality therapies.

Despite this, the speciality market is on the verge of seeing huge shifts. Competition from biosimilar and generic versions of these treatments is expected to increase over the next few years, which will impact the market for biologic as well as traditional specialty pharmaceuticals.

• The distribution of COVID-19 vaccinations has contributed to an increase in the sales and earnings of retail pharmacies.
• The distribution of COVID-19 vaccinations has been significantly aided by the participation of pharmacies.
• About 200 million doses of the COVID-19 vaccination were administered by retail pharmacies in 2021, and this number does not include the doses that were delivered as part of the long-term care pharmacy program.

During the first five weeks of the year 2022, pharmacies provided an additional around 29 million doses to patients. We estimate that total pharmacy revenues (and gross profits) from the administration of COVID-19 vaccinations were greater than $7.5 billion until the end of 2021.

This figure includes both sales and profits. The COVID-19 vaccinations contributed around fifty percent of a pharmacy’s total income, which was the operational profit. The prescription dispensing data that are listed above do not include income from the administration of COVID-19 vaccinations since this will allow for easier comparison with figures from prior years.

The following are some of the major firms that are anticipated to undergo organizational shifts between now and 2022: In order to become one of the leading specialized pharmacy operators, Centene has recently completed a number of acquisitions of other businesses.

On the other hand, the business has plans to contract out the management of its PBM activities to a third party. It is very possible that this will entail the sale of its speciality pharmaceutical assets. It was just fifteen months ago that it bought PANTHERx Rare Pharmacy, but it appears that the company has already started the process of selling it.

As I forecasted the year before, Walgreens saw a decline in revenues from its specialty pharmacies in 2021, and I anticipate an even larger decline in 2022. AllianceRx Walgreens Prime (ARxWP) is no longer the exclusive option for Prime Therapeutics’ PBM beneficiaries when it comes to mail-order and specialty pharmacy services.

A significant number of Prime’s plan sponsor customers have moved their business to Express Scripts. Walgreens has estimated that the loss of these customers will result in a decrease in revenue for ARxWP of $8 billion in both 2021 and 2022. (It should be noted that Walgreens also purchased Prime’s 45% ownership stake in ARxWP.) In addition to this, the specialty pharmacy coverage for the Federal Employee Program (FEP) was transferred back to CVS Health in January 2022.

Prime was not able to retain this business. According to our best estimates, ARxWP brought in around $3.7 billion in income from speciality sales in 2021 thanks to this arrangement. Our ranking of the top 15 will continue to change, but it is still too early to speculate on the order in which the firms will finish.

1. NOTES FOR NERDS It is possible that the statistics we have projected for the revenue from prescriptions do not correlate with the estimates from other public sources.
2. Because of these factors: On the basis of a calendar year, we have either calculated or estimated the data.
3. Many publicly traded firms in the retail industry do not align their fiscal years with the calendar year.

Many corporations do not reveal prescription revenues. As a result, we have estimated the data using a number of different approaches and sources. We have made a variety of modifications, as mentioned in the footnotes to the chart that is located above, to account for the pro forma impact of mergers and acquisitions, in addition to specific client transfers, among the biggest PBMs.

• These footnotes are located above the table.
• Additionally, year-over-year growth rates were calculated using the preceding year’s pro forma sales as the basis for comparison.
• When calculating pro forma revenues, the year in which a merger or acquisition was finalized is used as the base year.
• The numbers for prescription dispensing revenues and profits in our new report (including the table above) do not include COVID-19 vaccines that were provided in retail pharmacies.

This is true unless it is specifically stated otherwise elsewhere in the report. This exclusion makes it possible to make comparisons with the statistics from earlier years that are more accurate. Another thing to keep in mind is that revenues from the dispensing of prescription drugs are not the same as the net spending on outpatient prescription drugs that is reported by the Centers for Medicare and Medicaid Services, nor are they the same as “non-discounted spending” or “invoice-price spending” (reported by IMS Health).

Is Walgreens the largest pharmacy?

CVS Health Corporation was the leading pharmacy in the United States in 2021 in terms of market share based on revenue from sales of prescription drugs. Walgreens Boots Alliance was in second place. At that time, CVS Health controlled close to 25 percent of the income generated by the market for prescription drugs.

1. The purchase of pharmaceutical benefit manager Express Scripts by Cigna in August 2018 resulted in a considerable rise in the company’s market share, according to the company’s reports.
2. Prior to that time, the majority of Cigna’s focus was on the insurance industry as well as products and services associated to it.

CVS pharmacies The CVS Health Corporation is a health care provider that operates across the entirety of the United States, as well as in Puerto Rico and Brazil. Retail outlets, medical clinics, and pharmacies are all a part of CVS health. Since 2005, there has been a significant growth in the number of pharmacies that are operated by CVS, according to latest estimates.

In terms of market share, CVS Health is also considered to be one of the two most successful specialty drug pharmacies in the United States. The market for pharmaceuticals and pharmacies The United States holds the biggest single share of revenue generated by the global pharmaceutical market. The cumulative number of prescriptions filled in the United States has been climbing steadily over the past few years and is projected to reach around 6.3 billion by the year 2020.

In recent years, the proportion of total U.S. health expenditures that is attributable to prescription medication costs has stayed unchanged, despite the fact that the value of prescription drug spending has been rising. On the other hand, the market for pharmacies has lately experienced a number of important shifts, particularly as a result of the expanding influence of online pharmacies and mail-order pharmacies throughout the world.